{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-004350","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2024-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.847994+00:00","generated_at":"2026-06-06T15:02:35.243571+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PAVmed elects stock payment of $4.7M fees from Lucid Diagnostics","bullets":["PAVmed received $4,675,256 of fees/reimbursements from Lucid Diagnostics via 3,331,771 shares of Lucid common stock.","Lucid Diagnostics is a majority-owned subsidiary of PAVmed.","Transaction described in more detail in Lucid Diagnostics' Form 8-K filed January 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-004350","json":"https://secwatch.observer/filing/0001493152-24-004350.json","markdown":"https://secwatch.observer/filing/0001493152-24-004350.md","text":"https://secwatch.observer/filing/0001493152-24-004350.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224004350/0001493152-24-004350-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224004350/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:02:35.243571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}